Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

ATAI
AtaiBeckley Inc. Common Stock
stock NASDAQ

Market Open
Jul 16, 2026 10:48:47 AM EDT
7.16USD+33.675%(+1.80)96,970,812
7.16Bid   7.17Ask   0.01Spread
Pre-market
Jul 16, 2026 9:29:32 AM EDT
7.06USD+31.716%(+1.70)8,644,204
After-hours
Jul 15, 2026 4:58:30 PM EDT
5.35USD+0.028%(+0.00)0
OverviewOption ChainMax PainOptionsPrice & VolumeDividendsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
10:13AM EST  Psyched: UK Streamlines MDMA Therapy, FDA OKs MindMed's First LSD Trial In 40 years, Atai Launches Subsidiary   Benzinga
Jan 27, 2022
12:37PM EST  ATAI Life Sciences Announces New Program To Discover Next-Generation Mental Health Treatments   Benzinga
07:58AM EST  The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study   Benzinga
07:39AM EST  ATAI Life Sciences Announces New Program To Discover Next-Generation Mental Health Treatments   Benzinga
07:25AM EST  Dalriada Drug Discovery To Collaborate With Atai Life Sciences' New Platform Company To 'Discover Next-Generation Therapies for Mental Health'   Benzinga
06:59AM EST  Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atais portfolio of new chemical entities (NCEs)   GlobeNewswire Inc
Jan 18, 2022
07:39AM EST  Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS   Benzinga
Jan 12, 2022
10:13AM EST  ATAI Life Sciences Option Alert: May 20 $15 Calls Sweep (3) near the Ask: 2057 @ $0.55 vs 316 OI; Earnings 2/23 Before Open [est] Ref=$6.65   Benzinga
08:30AM EST  The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award   Benzinga
07:06AM EST  Atai Life Sciences Announces FDA IND Clearance For PCN-101 R-ketamine Program   RTTNews
06:59AM EST  atai Life Sciences announces FDA Investigational New Drug (IND)   GlobeNewswire Inc
Jan 10, 2022
01:03PM EST  atai Life Sciences N.V. (Nasdaq: ATAI) (atai), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference today:   GlobeNewswire Inc
Dec 30, 2021
09:37AM EST  2021 Was The Year Psychedelics Conquered Capitalism...Or Is It The Other Way Around?   Benzinga
Dec 17, 2021
07:30AM EST  Armada Acquisition Corp. I to acquire Rezolve Mobile Engagement   GlobeNewswire Inc
Dec 16, 2021
06:59AM EST  atai Impacts first major initiative will support promising academics in researching the therapeutic potential of psychedelic compounds to address unmet needs in mental health   GlobeNewswire Inc
Dec 15, 2021
10:20AM EST  Mid-Morning Market Update: Markets Open Lower; US Retail Sales Miss Estimates   Benzinga
06:57AM EST  Apeiron and other key shareholders enter into voluntary lock-up agreementsThis voluntary lock-up extends trading restrictions by 24 months for Apeiron and 12 months for other investorsDemonstrates strong ongoing confidence in atais diversified platform and multiple innovative programs designed to address unmet patient need in mental health   GlobeNewswire Inc
Dec 14, 2021
07:41AM EST  Atai Says Positive Topline Data From Phase 2a Study Of RL-007 For Cognitive Impairment Associated With Schizophrenia   RTTNews
07:30AM EST  RL-007 was well tolerated and demonstrated a clinically meaningful pro-cognitive profile   GlobeNewswire Inc
Dec 13, 2021
06:59AM EST  atai Life Sciences Has Been Selected for Addition to the NASDAQ   GlobeNewswire Inc
Dec 9, 2021
09:56PM EST  Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study   Benzinga
09:37PM EST  National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000   Benzinga
10:30AM EST  TryptageniX, a majority-owned joint venture with CB Therapeutics, employs bioprospecting to develop new chemical entities with potential applications in mental health.   GlobeNewswire Inc
Dec 7, 2021
01:50PM EST  New York's Horizons Psychedelic Conference Highlights Big Donations In The Growing Industry   Benzinga
Nov 30, 2021
04:55PM EST  Analyst Ratings For ATAI Life Sciences   Benzinga
04:51PM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021   Benzinga
04:49PM EST  Maxim Group Initiates Coverage On ATAI Life Sciences with Buy Rating, Announces Price Target of $25   Benzinga
04:15PM EST  Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways   Benzinga
Nov 29, 2021
07:08AM EST  atai Life Sciences Increases Its Ownership Position In COMPASS Pathways From 19.4% To 20.8%   Benzinga
07:00AM EST  Demonstrates atais confidence in COMPASS Phase 2b data and its potential for patients with treatment-resistant depression   GlobeNewswire Inc
Nov 22, 2021
06:28AM EST  HC Wainwright & Co. Maintains Buy on ATAI Life Sciences, Raises Price Target to $50   Benzinga
Nov 16, 2021
09:12AM EST  Credit Suisse Maintains Outperform on ATAI Life Sciences, Lowers Price Target to $24   Benzinga
07:04AM EST  RBC Capital Maintains Sector Perform on ATAI Life Sciences, Lowers Price Target to $17   Benzinga
Nov 15, 2021
11:07AM EST  Earnings Scheduled For November 15, 2021   Benzinga
10:52AM EST  ATAI Life Sciences Q3 EPS $(0.21) Misses $(0.20) Estimate   Benzinga
06:59AM EST  atai Life Sciences Reports Third Quarter 2021 Financial Results   GlobeNewswire Inc
Nov 11, 2021
12:10PM EST  Analyst Ratings For ATAI Life Sciences   Benzinga
10:01AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2021   Benzinga
06:17AM EST  Roth Capital Initiates Coverage On ATAI Life Sciences with Buy Rating, Announces Price Target of $32   Benzinga
Nov 8, 2021
08:30AM EST  atai Life Sciences N.V. (Nasdaq: ATAI) (atai), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, November 15, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and provide a business update.   GlobeNewswire Inc
Nov 5, 2021
04:30PM EDT  atai Life Sciences N.V. (Nasdaq: ATAI) (atai), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,today announced that it will participate in the following upcoming investor conferences in November:   GlobeNewswire Inc
Nov 2, 2021
05:20PM EDT  This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop   Benzinga
Nov 1, 2021
09:09AM EDT  atai Life Sciences Announces Supportive Interim Data From First 8-Patient Cohort Of Phase 2a Trial For Novel Treatment Of Cognitive Impairment Associated With Schizophrenia   Benzinga
09:00AM EDT  atai Life Sciences (Nasdaq: ATAI) ("atai") today announced thatit has observed encouraging interimdata from the first 8-patient cohort of its Phase 2a trial,demonstrating potential pro-cognitive effectsofitscompound RL-007, a cholinergic, glutamatergic, and GABA type B receptor modulator,forCognitive Impairment Associated with Schizophrenia (CIAS).   GlobeNewswire Inc
Oct 19, 2021
07:20AM EDT  atai Life Sciences Launches atai Impact, A Philanthropic Program To Harness The Power Of Innovative Mental Health Approaches For Positive Social Change   Benzinga
07:00AM EDT  atai Life Sciences (Nasdaq: ATAI) (atai), a clinical-stage biopharmaceutical company, today announced the launch of its new philanthropic program, atai Impact, in line with atai Life Sciences vision, to heal mental health disorders so that everyone, everywhere can live a more fulfilled life.   GlobeNewswire Inc
Oct 18, 2021
01:37PM EDT  Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation   Benzinga
10:22AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2021   Benzinga
06:30AM EDT  HC Wainwright & Co. Initiates Coverage On ATAI Life Sciences with Buy Rating, Announces Price Target of $40   Benzinga
Oct 13, 2021
04:25PM EDT  There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are   Benzinga
Oct 11, 2021
03:45PM EDT  What Is Precision Psychiatry? Biotech Company Leverages New Approach To Mental Health Disorders   Benzinga
10:42AM EDT  Atai Life Launches Depression-Focused Firm   Benzinga
08:09AM EDT  Atai Life Sciences Announces The Launch Of PsyProtix, To Develop A Precision Psychiatry Approach For Treatment-resistant Depression   Benzinga
08:00AM EDT  atai Life Sciences announces the launch of PsyProtix, to develop a   GlobeNewswire Inc
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Sep 27, 2021
09:19AM EDT  Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study   Benzinga
Sep 21, 2021
01:20PM EDT  Can Ibogaine Treat Opioid Addiction? Nasdaq-Listed Atai Is Launching A Trial To Find Out   Benzinga
09:50AM EDT  ATAI Life Sciences shares were trading higher after the company announced its subsidiary, DemeRx, dosed the first subject in a Phase 1/2a study of DMX-1002 in opioid use disorder.   Benzinga
08:04AM EDT  ATAI Life Sciences Subsidiary DemeRx Doses First Subject In Phase 1/2a Study Of DMX-1002 In Opioid Use Disorder   Benzinga
08:00AM EDT  DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002   GlobeNewswire Inc
Sep 20, 2021
12:51PM EDT  Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial   Benzinga
Sep 17, 2021
07:53PM EDT  Can Ketamine For Depression Be Improved? New Study Will Look Into Ketamine Analog Arketamine   Benzinga
Sep 15, 2021
08:10AM EDT  atai Life Sciences Increases Loan in Principal by US$6m to Support   GlobeNewswire Inc
Sep 14, 2021
02:59PM EDT  Can Ketamine For Depression Be Improved? New Study Will Looks Into Ketamine Analog Arketamine   Benzinga
12:54PM EDT  Meet The Top 12 CEOs In The Psychedelics Industry   Benzinga
08:05AM EDT  Perception Neuroscience Initiates Phase 2a Study Of PCN-101 For Treatment Resistant Depression   Benzinga
08:00AM EDT  Perception Neuroscience initiates Phase 2a study of PCN-101   GlobeNewswire Inc
Sep 13, 2021
01:37PM EDT  Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics   Benzinga
12:48PM EDT  Meet The Top 12 CEOs In The Psychedelics Industry   Benzinga
Sep 9, 2021
04:46PM EDT  Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry?   Benzinga
04:30PM EDT  atai Life Sciences and Introspect Digital Therapeutics to test   GlobeNewswire Inc
Sep 3, 2021
06:00PM EDT  atai Life Sciences N.V. (Nasdaq: ATAI) (atai), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,today announced that it will participate in in the following upcoming investor conferences in September:   GlobeNewswire Inc
Sep 1, 2021
12:46PM EDT  What 10 Analyst Ratings Have To Say About ATAI Life Sciences   Benzinga
10:13AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2021   Benzinga
08:22AM EDT  Jefferies Initiates Coverage On ATAI Life Sciences with Buy Rating, Announces Price Target of $27   Benzinga
06:07AM EDT  The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 5.45 A.M. EDT).   RTTNews
Aug 21, 2021
11:24AM EDT  Where ATAI Life Sciences Stands With Analysts   Benzinga
Aug 17, 2021
12:41PM EDT  What 9 Analyst Ratings Have To Say About ATAI Life Sciences   Benzinga
10:11AM EDT  Argus Research Maintains Buy on ATAI Life Sciences, Raises Price Target to $27   Benzinga
10:10AM EDT  Aegis Capital Maintains Buy on ATAI Life Sciences, Raises Price Target to $27   Benzinga
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 16, 2021
03:26PM EDT  ATAI Life Sciences shares were trading lower after the company reported worse-than-expected Q2 financial results.   Benzinga
08:42AM EDT  Psyched: Atai Launches 'Salvia Divinorum' Subsidiary, Mindset, Psilera and Wesana's Preclinical Trials, Origin Raises $5M   Benzinga
07:24AM EDT  Atai Life Sciences Q2 Loss Per Share $0.37 Vs Loss $0.18 Last Year   RTTNews
07:03AM EDT  ATAI Life Sciences Q2 EPS $(0.37) Misses $0.01 Estimate   Benzinga
07:00AM EDT  -Successfully completed Initial Public Offering on Nasdaq raising $258.8 million in gross proceeds, including the underwriters over-allotment-   GlobeNewswire Inc
04:04AM EDT  Earnings Scheduled For August 16, 2021   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 12, 2021
01:20PM EDT  Peter Thiel Backed Atai Life Launches New Mental Health Disorders-Focused Company   Benzinga
09:29AM EDT  Atai Launches Revixia Life Sciences To Develop Salvinorin A For Variety Of Mental Health Conditions   Benzinga
08:50AM EDT  ataiLife Sciences(Nasdaq: ATAI)("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of Revixia Life Sciences (Revixia), a wholly owned subsidiary developing Salvinorin A (SalA) to treat a variety of mental health disorders.   GlobeNewswire Inc
06:59AM EDT  Atai Life Sciences To Research Potent Psychedelic Herb Salvia Divinorum Through Its New Subsidiary   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 10, 2021
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 9, 2021
08:26PM EDT  Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies   Benzinga
Aug 6, 2021
06:10PM EDT  atai Life Sciences N.V. (Nasdaq: ATAI) (atai), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity Growth Conference, to be held virtually from August 10-12, 2021.   GlobeNewswire Inc
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 3, 2021
02:25PM EDT  Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies   Benzinga
Aug 2, 2021
10:08AM EDT  Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected   Benzinga
Jul 28, 2021
05:32PM EDT  Atai Launches New "Nose-To-Brain" Drug Delivery Company To Interact With Its Portfolio Of Psychedelics Subsidiaries   Benzinga
09:13AM EDT  ATAI Life Sciences Highlights Launch Of InnarisBio   Benzinga
09:12AM EDT  atai Life Sciences launches InnarisBio, in partnership with the   GlobeNewswire Inc
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 23, 2021
06:10PM EDT  Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To 'Psychedelics Renaissance'   Benzinga
05:04PM EDT  Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance"   Benzinga
Jul 19, 2021
07:24AM EDT  Psyched: Investment Banks Bullish On Atai Life Sciences, Wesana's $17M Purchase Of PsyTech, Creso Pharma Acquires Halucenex   Benzinga
Jul 16, 2021
03:56PM EDT  Investment Banks Bullish On Psychedelics Co Atai Life Sciences: Cantor, Credit Suisse, Citigroup, Cowen, Aegis And Others Launch Coverage, Positive Ratings   Benzinga
Jul 15, 2021
02:46PM EDT  Palo Santo: New Venture Capital Group Raises $35M To Focus On Psychedelic Medicine   Benzinga
09:04AM EDT  Leading U.S.-Based Psychedelic Healthcare VC Fund Launches with $35 Million   PR Newswire
Jul 14, 2021
10:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2021   Benzinga
06:04AM EDT  Baader Helvea Initiates Coverage On ATAI Life Sciences with Buy Rating, Announces Price Target of $21   Benzinga
Jul 13, 2021
10:21AM EDT  UPDATE: Credit Suisse On Atai Life Sciences: Firm Highlights 3 Fundamental Principles For Co. Platform Including Disciplined Program Selection With Prior Evidence In Humans, Decentralized operations With Shared Resources, & Optimized Capital Allocation   Benzinga
10:20AM EDT  UPDATE: Credit Suisse On Atai Life Sciences Outperform Initiation: Firm Sees Diversified NeuroPsych Platform With 'Material Exposure To Psychedelics' With Co. Programs Covering Depression, Substance Use Disorder, Cognitive Impairment, Anxiety, & PTSD   Benzinga
10:13AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021   Benzinga
08:53AM EDT  Cowen & Co. Initiates Coverage On ATAI Life Sciences with Outperform Rating   Benzinga
08:50AM EDT  Citigroup Initiates Coverage On ATAI Life Sciences with Buy Rating, Announces Price Target of $26   Benzinga
08:45AM EDT  Berenberg Initiates Coverage On ATAI Life Sciences with Buy Rating, Announces Price Target of $35   Benzinga
08:30AM EDT  Cantor Fitzgerald Initiates Coverage On ATAI Life Sciences with Overweight Rating, Announces Price Target of $45   Benzinga
07:49AM EDT  Credit Suisse Initiates Coverage On ATAI Life Sciences with Outperform Rating, Announces Price Target of $25   Benzinga
07:37AM EDT  RBC Capital Initiates Coverage On ATAI Life Sciences with Sector Perform Rating, Announces Price Target of $19   Benzinga
06:17AM EDT  Canaccord Genuity Initiates Coverage On ATAI Life Sciences with Buy Rating   Benzinga
Jul 8, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2021   Benzinga
09:34AM EDT  Aegis Capital Initiates Coverage On ATAI Life Sciences with Buy Rating, Announces Price Target of $26   Benzinga
Jul 7, 2021
07:47PM EDT  atai Life Sciences N.V. (Nasdaq: ATAI) (atai), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that it will present and participate in one-on-one investor meetings at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on July 13, 2021.   GlobeNewswire Inc
01:51PM EDT  Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies   Benzinga
Jun 21, 2021
10:22AM EDT  Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform   Benzinga
Jun 18, 2021
05:12PM EDT  Peter Thiel-Backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public   Benzinga
11:32AM EDT  ATAI Life Sciences Shares Open For Trade At $21; IPO Priced At $15/Share   Benzinga
10:42AM EDT  ATAI Life Sciences Shares Indicating $19.50 On 217K Shares   Benzinga
09:24AM EDT  ATAI Life Sciences Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $15/Share   Benzinga
12:28AM EDT  Atai Life Sciences Prices IPO Of 15 Mln Common Shares At $15/Shr   RTTNews
Jun 17, 2021
11:21PM EDT  atai Life Sciences Announces Pricing of Upsized Initial Public   GlobeNewswire Inc
Jun 11, 2021
02:51PM EDT  Peter Thiel-Backed Psychedelic Firm Atai Sets Terms For US IPO, Sees $2.3B Valuation   Benzinga
08:00AM EDT  atai Life Sciences Sees IPO Of ~14M Shares In $13-$15/Share Range; Has Applied To List On Nasdaq Under 'ATAI'   Benzinga
07:59AM EDT  atai Life Sciences Announces Launch of Initial Public Offering   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC